Modelling the MYC-driven Normal-to-tumour Switch in Breast Cancer

Overview

Journal Dis Model Mech

Specialty General Medicine

Date 2019 Jul 28

PMID 31350286

Citations 11

Authors

Corey Lourenco

Manpreet Kalkat

Kathleen E Houlahan

Jason De Melo

Joseph Longo

Susan J Done

Paul C Boutros

Linda Z Penn

Affiliations

Soon will be listed here.

Abstract

The potent MYC oncoprotein is deregulated in many human cancers, including breast carcinoma, and is associated with aggressive disease. To understand the mechanisms and vulnerabilities of MYC-driven breast cancer, we have generated an model that mimics human disease in response to MYC deregulation. MCF10A cells ectopically expressing a common breast cancer mutation in the phosphoinositide 3 kinase pathway (PIK3CA) led to the development of organised acinar structures in mice. Expressing both PIK3CA and deregulated MYC led to the development of invasive ductal carcinoma. Therefore, the deregulation of MYC expression in this setting creates a MYC-dependent normal-to-tumour switch that can be measured These MYC-driven tumours exhibit classic hallmarks of human breast cancer at both the pathological and molecular level. Moreover, tumour growth is dependent upon sustained deregulated MYC expression, further demonstrating addiction to this potent oncogene and regulator of gene transcription. We therefore provide a MYC-dependent model of breast cancer, which can be used to assay tumour signalling pathways, proliferation and transformation from normal breast acini to invasive breast carcinoma. We anticipate that this novel MYC-driven transformation model will be a useful research tool to better understand the oncogenic function of MYC and for the identification of therapeutic vulnerabilities.

Citing Articles

mA inhibition fuels oncolytic virus-elicited antitumor immunity via downregulating MYC/PD-L1 signaling.

Li S, Feng T, Liu Y, Yang Q, Song A, Wang S Int J Oral Sci. 2024; 16(1):36.

PMID: 38730256 PMC: 11087574. DOI: 10.1038/s41368-024-00304-0.

Topoisomerase 1 Inhibition in MYC-Driven Cancer Promotes Aberrant R-Loop Accumulation to Induce Synthetic Lethality.

Lin P, Lourenco C, Cruickshank J, Palomero L, van Leeuwen J, Tong A Cancer Res. 2023; 83(24):4015-4029.

PMID: 37987734 PMC: 10722143. DOI: 10.1158/0008-5472.CAN-22-2948.

MYC acetylated lysine residues drive oncogenic cell transformation and regulate select genetic programs for cell adhesion-independent growth and survival.

Hurd M, Pino J, Jang K, Allevato M, Vorontchikhina M, Ichikawa W Genes Dev. 2023; 37(19-20):865-882.

PMID: 37852796 PMC: 10691474. DOI: 10.1101/gad.350736.123.

Splice-switch oligonucleotide-based combinatorial platform prioritizes synthetic lethal targets CHK1 and BRD4 against MYC-driven hepatocellular carcinoma.

Thng D, Toh T, Pigini P, Hooi L, Dan Y, Chow P Bioeng Transl Med. 2023; 8(1):e10363.

PMID: 36684069 PMC: 9842033. DOI: 10.1002/btm2.10363.

3D chromatin remodeling potentiates transcriptional programs driving cell invasion.

Lebeau B, Jangal M, Zhao T, Wong C, Wong N, Cepeda Canedo E Proc Natl Acad Sci U S A. 2022; 119(36):e2203452119.

PMID: 36037342 PMC: 9457068. DOI: 10.1073/pnas.2203452119.

References

Boxer R, Jang J, Sintasath L, Chodosh L . Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell. 2004; 6(6):577-86. DOI: 10.1016/j.ccr.2004.10.013. View

Stone J, de Lange T, Ramsay G, Jakobovits E, Bishop J, Varmus H . Definition of regions in human c-myc that are involved in transformation and nuclear localization. Mol Cell Biol. 1987; 7(5):1697-709. PMC: 365270. DOI: 10.1128/mcb.7.5.1697-1709.1987. View

Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X . Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016; 534(7605):47-54. PMC: 4910866. DOI: 10.1038/nature17676. View

Eilers M, Picard D, Yamamoto K, Bishop J . Chimaeras of myc oncoprotein and steroid receptors cause hormone-dependent transformation of cells. Nature. 1989; 340(6228):66-8. DOI: 10.1038/340066a0. View

Kalkat M, Resetca D, Lourenco C, Chan P, Wei Y, Shiah Y . MYC Protein Interactome Profiling Reveals Functionally Distinct Regions that Cooperate to Drive Tumorigenesis. Mol Cell. 2018; 72(5):836-848.e7. DOI: 10.1016/j.molcel.2018.09.031. View

Lustig L, Dingar D, Tu W, Lourenco C, Kalkat M, Inamoto I . Inhibiting MYC binding to the E-box DNA motif by ME47 decreases tumour xenograft growth. Oncogene. 2017; 36(49):6830-6837. DOI: 10.1038/onc.2017.275. View

Hsu T, Simon L, Neill N, Marcotte R, Sayad A, Bland C . The spliceosome is a therapeutic vulnerability in MYC-driven cancer. Nature. 2015; 525(7569):384-8. PMC: 4831063. DOI: 10.1038/nature14985. View

Sato M, Rodriguez-Barrueco R, Yu J, Do C, Silva J, Gautier J . MYC is a critical target of FBXW7. Oncotarget. 2015; 6(5):3292-305. PMC: 4413654. DOI: 10.18632/oncotarget.3203. View

Kadota M, Yang H, Gomez B, Sato M, Clifford R, Meerzaman D . Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines. PLoS One. 2010; 5(2):e9201. PMC: 2821407. DOI: 10.1371/journal.pone.0009201. View

10.

Pajic A, Spitkovsky D, Christoph B, Kempkes B, Schuhmacher M, Staege M . Cell cycle activation by c-myc in a burkitt lymphoma model cell line. Int J Cancer. 2000; 87(6):787-93. DOI: 10.1002/1097-0215(20000915)87:6<787::aid-ijc4>3.0.co;2-6. View

11.

Sabo A, Kress T, Pelizzola M, de Pretis S, Gorski M, Tesi A . Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis. Nature. 2014; 511(7510):488-492. PMC: 4110711. DOI: 10.1038/nature13537. View

12.

Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov J . Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011; 27(12):1739-40. PMC: 3106198. DOI: 10.1093/bioinformatics/btr260. View

13.

Kalkat M, De Melo J, Hickman K, Lourenco C, Redel C, Resetca D . MYC Deregulation in Primary Human Cancers. Genes (Basel). 2017; 8(6). PMC: 5485515. DOI: 10.3390/genes8060151. View

14.

Chen Y, Olopade O . MYC in breast tumor progression. Expert Rev Anticancer Ther. 2008; 8(10):1689-98. PMC: 3027840. DOI: 10.1586/14737140.8.10.1689. View

15.

Wasylishen A, Chan-Seng-Yue M, Bros C, Dingar D, Tu W, Kalkat M . MYC phosphorylation at novel regulatory regions suppresses transforming activity. Cancer Res. 2013; 73(21):6504-15. DOI: 10.1158/0008-5472.CAN-12-4063. View

16.

Debnath J, Muthuswamy S, Brugge J . Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods. 2003; 30(3):256-68. DOI: 10.1016/s1046-2023(03)00032-x. View

17.

Pelengaris S, Littlewood T, Khan M, Elia G, Evan G . Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell. 1999; 3(5):565-77. DOI: 10.1016/s1097-2765(00)80350-0. View

18.

Leng N, Dawson J, Thomson J, Ruotti V, Rissman A, Smits B . EBSeq: an empirical Bayes hierarchical model for inference in RNA-seq experiments. Bioinformatics. 2013; 29(8):1035-43. PMC: 3624807. DOI: 10.1093/bioinformatics/btt087. View

19.

Pelengaris S, Khan M, Evan G . Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell. 2002; 109(3):321-34. DOI: 10.1016/s0092-8674(02)00738-9. View

20.

Lin C, Loven J, Rahl P, Paranal R, Burge C, Bradner J . Transcriptional amplification in tumor cells with elevated c-Myc. Cell. 2012; 151(1):56-67. PMC: 3462372. DOI: 10.1016/j.cell.2012.08.026. View